Antitrust Antitrust

Australia's Mayne Pharma agrees to $25 million settlement for not disclosing US price-fixing allegations

By Saloni Sinha
  • 09 Jul 2024 07:15
  • 09 Jul 2024 07:15
South Australia-based pharmaceutical company Mayne Pharma has agreed to pay A$38 million ($25 million) to settle an Australian shareholder class action lawsuit over the company's failure to disclose alleged anticompetitive conduct in the United States.
In a statement to the Australian Securities Exchange, or ASX, this week, Mayne Pharma said

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

Latest News